From Name

From Email

To Name

To Email

Message

Data shows 6 month duration for revance DaxibotulinumtoxinA

from MedEsthetics

Data shows 6 month duration for revance DaxibotulinumtoxinA MedEsthetics Revance Therapeutics announced results for two Phase 2a open-label, dose escalation studies of its investigational drug candidate DaxibotulinumtoxinA for Injection in the treatment of dynamic forehead lines (FHL) following glabellar (frown) line injections and lateral canthal lines (LCL). Both studies demonstrated positive efficacy results and that DaxibotulinumtoxinA for Injection was well tolerated. Additionally, the studies evaluated a range of doses, providing directional guidance on the impact of dose on efficacy and duration of effect. READ MORE

more